Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.36 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588600 | 0.86 | NOD1 (0.45) | EPHX1MMP8NOD1PLA2G2APLA2G5 | |
| SCHEMBL14906355 | 0.86 | NOD1 (0.45) | EPHX1MMP8NOD1PLA2G2APLA2G5 | |
| SCHEMBL15044803 | 0.81 | NOD1 (0.38) | EPHX1NOD1DNM1LMNAMAPK1 | |
| SCHEMBL15044794 | 0.80 | NOD1 (0.37) | NOD1DNM1KMT2AGGPS1 | |
| SCHEMBL20813983 | 0.79 | PLA2G2A (0.41) | EPHX1MMP8NOD1PLA2G2APLA2G5 | |
| SCHEMBL15044748 | 0.79 | GPR84 (0.44) | FAAHGRIK1GRIK2 | |
| SCHEMBL15044788 | 0.79 | GPR84 (0.46) | NOD1MEN1KMT2A | |
| SCHEMBL15044893 | 0.77 | NOD1 (0.39) | EPHX1NOD1FAAHDNM1LMNA | |
| SCHEMBL15044790 | 0.77 | GGPS1 (0.42) | FAAHDNM1LMNAMEN1MAPK1 | |
| SCHEMBL25051792 | 0.77 | KISS1R (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180036333-A9 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-02-08 | — | — | US | disclosed |
| US-20170165290-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-06-15 | — | — | US | disclosed |
| US-9512073-B2 | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20130158021-A1 | AMINO ACID-, PEPTIDE-AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165290-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | EPHX1 2716/4885MMP8 2913/4885NOD1 2381/4885 |
| US-20180036333-A9 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | EPHX1 2716/4885MMP8 2913/4885NOD1 2381/4885 |
| US-20130158021-A1 | AMINO ACID-, PEPTIDE-AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | EPHX1 2716/4885MMP8 2913/4885NOD1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.